Y-Intercept (HK)’s Vanda Pharmaceuticals VNDA Stock Holding History

Y-Intercept (HK)’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.8M	Buy	+294,131	New	+$1.92M	0.04%	758
2024 Q3	–	Sell	-10,594	Closed	-$59.9K	–	1842
2024 Q2	$59.9K	Buy	+10,594	New	+$54.7K	﹤0.01%	1290
2023 Q4	–	Sell	-162,475	Closed	-$702K	–	1679
2023 Q3	$702K	Buy	+162,475	New	+$903K	0.07%	434
2023 Q2	–	Sell	-42,743	Closed	-$290K	–	1756
2023 Q1	$290K	Sell	42,743 -15,338	-26%	-$108K	0.03%	791
2022 Q4	$429K	Buy	+58,081	New	+$566K	0.06%	491

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Y-Intercept (HK)'s VNDA Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Vanda Pharmaceuticals (VNDA) in Q2 2026: 294,131 shares worth $1.8M. The stake represents 0.04% of the portfolio and ranks #758 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in VNDA as recently as Q2 2024.

Y-Intercept (HK) first reported a position in VNDA in Q4 2022 and has held it in 5 quarters since. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Y-Intercept (HK) held 294,131 shares of Vanda Pharmaceuticals worth $1.8M as of Q2 2026.
Vanda Pharmaceuticals was a new Y-Intercept (HK) position in Q2 2026.
Vanda Pharmaceuticals made up 0.04% of Y-Intercept (HK)'s portfolio in Q2 2026, its #758 holding.
Y-Intercept (HK) first reported a position in Vanda Pharmaceuticals in Q4 2022 and has held it in 5 quarters since.
172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.